Sherry A. Goodner

499 total citations
19 papers, 350 citations indexed

About

Sherry A. Goodner is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Sherry A. Goodner has authored 19 papers receiving a total of 350 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Sherry A. Goodner's work include Cancer Treatment and Pharmacology (4 papers), Lung Cancer Research Studies (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Sherry A. Goodner is often cited by papers focused on Cancer Treatment and Pharmacology (4 papers), Lung Cancer Research Studies (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Sherry A. Goodner collaborates with scholars based in United States, Netherlands and Canada. Sherry A. Goodner's co-authors include Paula M. Fracasso, Matthew A. Arquette, L. Wright, Ramaswamy Govindan, Feng Gao, Janet S. Rader, Joel Picus, Howard A. Burris, Suzanne F. Jones and Gregory M. Springett and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Sherry A. Goodner

19 papers receiving 337 citations

Peers

Sherry A. Goodner
Patrick Cobb United States
Cristina Teragni Italy
Scott A. Soefje United States
V J O'Neill United Kingdom
Aiman Shalabi United States
James D Mellor Australia
Carla Masini Italy
Vince D. Cataldo United States
Kelly A. Harmon United States
Alice G. Ettinger United States
Patrick Cobb United States
Sherry A. Goodner
Citations per year, relative to Sherry A. Goodner Sherry A. Goodner (= 1×) peers Patrick Cobb

Countries citing papers authored by Sherry A. Goodner

Since Specialization
Citations

This map shows the geographic impact of Sherry A. Goodner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sherry A. Goodner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sherry A. Goodner more than expected).

Fields of papers citing papers by Sherry A. Goodner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sherry A. Goodner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sherry A. Goodner. The network helps show where Sherry A. Goodner may publish in the future.

Co-authorship network of co-authors of Sherry A. Goodner

This figure shows the co-authorship network connecting the top 25 collaborators of Sherry A. Goodner. A scholar is included among the top collaborators of Sherry A. Goodner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sherry A. Goodner. Sherry A. Goodner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Fracasso, Paula M., George A. Fisher, Sherry A. Goodner, et al.. (2023). A Phase I Trial of the ABCB1 Inhibitor, Oral Valspodar, in Combination With Paclitaxel in Patients With Advanced Solid Tumors. American Journal of Clinical Oncology. 46(8). 353–359. 6 indexed citations
2.
Fracasso, Paula M., Linda Duska, Premal H. Thaker, et al.. (2022). An Exploratory Study of Neoadjuvant Cetuximab Followed by Cetuximab and Chemoradiotherapy in Women With Newly Diagnosed Locally Advanced Cervical Cancer. American Journal of Clinical Oncology. 45(7). 286–293. 2 indexed citations
3.
Fracasso, Paula M., Sherry A. Goodner, Michael Naughton, et al.. (2022). A Phase I Study of Apolizumab, an Anti-HLA-DR ß-chain Monoclonal Antibody, in Patients With Solid Tumor Malignancies. American Journal of Clinical Oncology. 45(7). 294–297. 2 indexed citations
4.
5.
Fracasso, Paula M., Sherry A. Goodner, Denise Foster, et al.. (2013). Coaching Intervention As a Strategy for Minority Recruitment to Cancer Clinical Trials. Journal of Oncology Practice. 9(6). 294–299. 23 indexed citations
6.
Fracasso, Paula M., Joel Picus, Sherry A. Goodner, et al.. (2008). Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin®, in resistant solid tumor malignancies. Cancer Chemotherapy and Pharmacology. 63(3). 451–458. 40 indexed citations
7.
Fracasso, Paula M., et al.. (2007). Coaching intervention as a strategy for enhancing accrual to phase I/II clinical trials. Journal of Clinical Oncology. 25(18_suppl). 6580–6580. 1 indexed citations
8.
Fracasso, Paula M., Howard A. Burris, Matthew A. Arquette, et al.. (2007). A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing. Clinical Cancer Research. 13(3). 986–993. 120 indexed citations
9.
Govindan, Ramaswamy, Wan‐Teck Lim, Matthew A. Arquette, et al.. (2006). A phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer. Oncology Reports. 15(1). 123–7. 1 indexed citations
10.
Fracasso, Paula M., Ramaswamy Govindan, Matthew J. Ellis, et al.. (2006). Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel (Taxoprexin) in resistant solid tumor malignancies. Journal of Clinical Oncology. 24(18_suppl). 2036–2036. 3 indexed citations
11.
Fracasso, Paula M., Kristie A. Blum, Benjamin Tan, et al.. (2005). Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. British Journal of Cancer. 93(1). 46–53. 24 indexed citations
12.
Fracasso, Paula M., Michelle A. Rudek, Michael Naughton, et al.. (2004). Phase I study combining UCN-01 with irinotecan in resistant solid tumor malignancies. Journal of Clinical Oncology. 22(14_suppl). 3139–3139. 2 indexed citations
13.
Fracasso, Paula M., Lori J. Goldstein, Dinesh P. de Alwis, et al.. (2004). Phase I Study of Docetaxel in Combination with the P-Glycoprotein Inhibitor, Zosuquidar, in Resistant Malignancies. Clinical Cancer Research. 10(21). 7220–7228. 62 indexed citations
14.
Fracasso, Paula M., Michelle A. Rudek, Michael Naughton, et al.. (2004). Phase I study combining UCN-01 with irinotecan in resistant solid tumor malignancies. Journal of Clinical Oncology. 22(14_suppl). 3139–3139. 7 indexed citations
15.
Fracasso, Paula M., Thomas J. Herzog, Sherry A. Goodner, et al.. (2003). Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies. Cancer. 98(3). 610–617. 13 indexed citations
16.
Fracasso, Paula M., Janet S. Rader, Ramaswamy Govindan, et al.. (2002). Phase I study of rubitecan and gemcitabine in patients with advanced malignancies. Annals of Oncology. 13(11). 1819–1825. 9 indexed citations
17.
Mahon, Suzanne M., et al.. (1994). Safe handling practices of cytotoxic drugs: the results of a chapter survey.. PubMed. 21(7). 1157–65. 26 indexed citations
18.
Goodner, Sherry A., et al.. (1988). Eating Disorders in the Elderly. Clinical Gerontologist. 7(3-4). 137–153. 2 indexed citations
19.
Goodner, Sherry A., et al.. (1986). Tube feeding: Is it ever necessary?. New Directions for Mental Health Services. 1986(31). 87–98. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Patrick Cobb Breakdown of academic impact, for papers by Cristina Teragni Breakdown of academic impact, for papers by Scott A. Soefje Breakdown of academic impact, for papers by V J O'Neill Breakdown of academic impact, for papers by Aiman Shalabi Breakdown of academic impact, for papers by James D Mellor Breakdown of academic impact, for papers by Carla Masini Breakdown of academic impact, for papers by Vince D. Cataldo Breakdown of academic impact, for papers by Kelly A. Harmon Breakdown of academic impact, for papers by Alice G. Ettinger
Rankless by CCL
2026